Development-stage pharmaceutical firm Avigen Inc. reiterated its intent to divest some assets and concentrate on developing different products in its Aug. 5 second quarter earnings release. The $68 million market cap company originally announced in a April 5 statement that it was looking to sell its gene therapy technology and instead focus on Parkinson’s disease treatments and other “traditional pharmaceutical products.”
To read the entire story, you must be logged in.
Please log in now or register with us.
